Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study. (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/rheumatology/keac167
PubMed Identifier: 35377447
Publication URI: http://europepmc.org/abstract/MED/35377447
Type: Journal Article/Review
Volume: 61
Parent Publication: Rheumatology (Oxford, England)
Issue: 12
ISSN: 1462-0324